Seroquel®/Seroquel XR® (quetiapine) – New warning

- On November 29, 2018, the FDA approved an update to the *Warnings and Precautions* section of the Seroquel (quetiapine) and Seroquel XR (quetiapine) drug labels regarding the risk of anticholinergic (antimuscarinic) effects.
    - Generic versions of Seroquel tablets and Seroquel XR extended-release tablets are available.
- Norquetiapine, an active metabolite of quetiapine, has moderate to strong affinity for several muscarinic receptor subtypes. This contributes to anticholinergic adverse reactions when quetiapine-containing products are used at therapeutic doses, taken concomitantly with other anticholinergic medications, or taken in overdose.
    - Quetiapine should be used with caution in patients receiving medications having anticholinergic (antimuscarinic) effects.
    - Constipation was a commonly reported adverse event in patients treated with quetiapine and represents a risk factor for intestinal obstruction. Intestinal obstruction has been reported with quetiapine, including fatal reports in patients who were receiving multiple concomitant medications that decrease intestinal motility.
    - Quetiapine should be used with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, or constipation, or increased intraocular pressure.
- Seroquel and Seroquel XR carry boxed warnings for increased mortality in elderly patients with dementia-related psychosis; and suicidal thoughts and behaviors